Related Experiment Video
Updated: Aug 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Barriers to recommendation of integrative oncology modalities in supportive care: a MASCC/SIO survey
Alexandre Chan1, Dalia Kagramanov2, Reem Nasr2
1Department of Clinical Pharmacy Practice, University of California Irvine, 802 W Peltason Drive, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.
Purpose:
Integrative oncology (IO) modalities aim to improve the quality of life of persons with cancer, including strategies to manage treatment and disease-related symptoms. As evidence increases to include IO in supportive care, interest grows globally. Understanding barriers to IO recommendation is key to facilitating its uptake.
Methods:
Members of the Multinational Association of Supportive Care in Cancer (MASCC) and the Society for Integrative Oncology (SIO) were invited to complete an online survey in Fall 2023 assessing barriers to IO recommendation on a 5-point scale. Descriptive statistics assessed demographic data and general counts of scaled agreement, while logistic regression analysis evaluated perceived barriers in relation to relevant covariates.
Results:
Over 80% of respondents believed that healthcare professionals' (HCP) lack of knowledge with IO and lack of insurance/out-of-pocket costs were barriers to recommending IO. Approximately 80% agreed that lack of referral pathways was a logistical barrier and 85% reported lack of confidence in IO as an individual-level barrier. Respondents from Europe were 2.2 times more likely to agree with the perceived barrier of HCP knowledge, compared to respondents from North America (OR 2.22, 95% CI 1.05-4.67, p = 0.036). Lastly, compared to general physicians, integrative professionals were more likely to report perceptions that IO would delay conventional care delivery (OR 3.62, 95% CI 1.56-8.43, p = 0.0003).
Conclusions:
Results of this study highlight important barriers and facilitators of IO integration into standard supportive care globally. These findings represent perspectives from an international sample of MASCC and SIO members and may not apply to all oncology professionals. Further research is necessary to understand the global roadblocks that exist among practitioners interested in IO use.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Tumor Immunotherapy
Ethical Issues
Ethical Concerns in Healthcare:
Treatment Resistent Cancers
